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Abstact 
Following pathogen infection, the IκB kinase (IKK) -
related kinases TBK1 and IKKi phosphorylate and 
activate members of the Interferon Regulatory Factor 
transcription factors that control the trans-cription of a 
repertoire of genes with anti-viral activity. Studies have 
revealed that these kinases also target NF-κB and c-Jun 
transcription factors thereby suggesting that they could 
also control inflammatory responses. The link betwen 
chronic inflammation and cancer is under intensive 
investigations, the canonical IκB kinases (IKKα and 
IKK β) and NF-κB being proposed as major culprits. 
New findings now suggest that the IKK-related kinases 
TBK1 and IKKi, in addition to their essential functions 
in controlling the innate immune response, also 
participate to signaling pathways that impact on cell
transformation and tumor prog-ression. This review 
will therefore discuss the role of TBK1 and IKKi in
innate immunity and summarize their proposed roles in 
cellular trans-formation and oncogenesis by focusing 
on their regulation and downstream substrates. 
Introduction 
Recognition of invading pathogens such as viruses and 
bacteria by cells is known to trigger the rapid activation 
of multiple latent transcription factors, namely NF-κB, 
AP-1 (ATF-2/c-Jun) and the Interferon Regulatory 
Factors (IRFs). Once activated, these transcription 
factors activate in turn a set of immunomodulatory 
genes that produce protein messengers in the form of 
cytokines. The best-characterized cytokines of the 
innate host defense to virus is the family of 
transcriptionally activated interferon (IFN) proteins, 
which includes type I IFN-α and IFN-β. Once  
produced, these secreted proteins act in autocrine and 
paracrine fashion to modulate gene expression throug  
engagement of cell surface type I IFN α/β receptor 
(IFNAR) and activation of the Jak-STAT signaling 
pathway. STAT1/2 heterodimers, in conjunction with 
interferon-stimulated gene factor 3γ (ISGF3γ/IRF-9) 
bind to interferon-stimulated response elements (ISRE) 
found in numerous type I IFN-induced genes, such as 
2'-5' oligoadenylate synthase, dsRNA activated kinase 
(PKR), RNA editing enzymes (APOBEC3, ADAR), 
IFN-Stimu-lated Genes (ISG)-56, -54 and -15, resulting 
in growth inhibition, apoptosis, and impaired viral gene 
expression and replication (Grandvaux et al., 2002b). 
Through their distinct effects on immune cells such as 
maturation of dendritic cells, clonal expansion of CD8+ 
T cells and stimulation of NK cells, type I IFNs also 
link innate and adaptive antiviral immunity 
(Theofilopoulos et al., 2005). 
Pattern Recognition Receptors involved 
in IFN type I production 
Following exposure to pathogen-associated mole-cular 
patterns (PAMPs), the innate immune response and the 
inflammation reaction that follows rely on 
evolutionarily conserved receptors termed pattern-
recognition receptors (PRRs). Some of these receptors 
are located at the plasma membrane and include 
molecules such as the Toll-like receptors (TLR 1, 2, 4, 
5, 6) and scavenger receptors (CD36 and SR-A). Others 
occur in acidic endosomes (TLR 3, 7, 8, and 9), and
still others can be found in the cytoplasm [PKR, the
RIG-I-like receptors (RLRs) (RIG-I and MDA5), the 
DNA-dependent activator of IRFs (DAI), and the 
nucleotide-binding oligomerization domain (NOD)  
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receptors] (Lee and Kim, 2007; Tamura et al., 2008). 
Whereas the vast majority of these PRRs induce 
intracellular signaling cascades leading to the activ tion 
of NF-κB and AP-1 transcription factors, only a subset 
of them, namely the nucleotide-sensing receptors 
(TLR3, -7, -8, -9, RIG-I and MDA5) and TLR4, which 
recognize bacterial lipopolysaccharide (LPS) and viral 
components such as respiratory syncytial virus F 
protein, will lead to the activation of IRF3 and -7 and 
type I IFN synthesis (see (Bowie and Unterholzner, 
2008) for a recent review). 
Signaling cascades leading to the 
activation of the NF-κB pathway 
The underlying mechanism controlling the activa-tion 
of NF-κB members began to be elucidated in 1997 
when the IKK complex was first discovered (DiDonato 
et al., 1997). In resting cells, NF-κB members are 
sequestered in the cytoplasm in inactive forms through 
their association with one of several inhibitory 
molecules, namely IκB-α, -β, -ε, p105, and p100. These 
inhibitors mask the nuclear localization signal (NLS) in 
the Rel Homology Domain (RHD) of NF-κB members, 
thereby preventing them from entering the nucleus (see 
(Perkins, 2007) for a recent review). The rate-limiting 
step in the activation of NF-κB members is therefore 
the phosphorylation-dependent degrada-tion of IκB-α, -
β, -ε. The best-characterized IκB protein is IκBα. 
Following PRR engagement or treatment with 
prototypical activators such as tumor necrosis factor 
(TNF)- α, IL-1β or phorbol 12- 
myristate 13-acetate (PMA), IκBα is phosphoryla-ted at 
Ser-32 and Ser-36 in the N-terminal signal responsive  
domain by the canonical IκB kinase (IKK) complex 
which is composed of two catalytic subunits called 
IKK α and β and one regulatory subunit called IKKγ or 
NF-κB essential modulator (NEMO) (Perkins, 2007). 
Phosphorylated IκBα is subsequently polyubiquitinated 
by the E3 ubiquitin ligase SCFβTrCP and targeted to the 
26S proteasome complex for degradation, resulting in 
the release and nuclear translocation of NF-κB 
members, which can now stimulate target gene 
transcription (Perkins, 2007). Alternative signaling 
pathways activating the NF-κB pathway have also been 
characterized (Perkins, 2007). They are classified as 
alternative pathways because they do not rely on the 
classical IKK complex. One such alternative pathway is 
the phosphorylation of p100 by IKKα homodimers, 
which leads to its processing to p52. 
Discovery of the IKK-related kinases 
The importance of the IKK complex in the regulation 
of NF-κB has fueled intensive research efforts by 
several groups leading to the discovery of the IKK-
related kinases (for detailed reviews, see (Hacker and 
Karin, 2006) and (Peters and Maniatis, 2001)). Using 
degenerate primers containing sequences common to 
IKK α and IKKβ, a portion of NF-κB-activating kinase 
(NAK) was amplified by PCR (Tojima et al., 2000). 
This NAK, also called TANK Binding Kinase 1 
(TBK1) or TRAF2-associated kinase (T2K), was 
shown to act as an IKK-activating kinase responsible 
for NF-κB activation in response to growth factors that 
stimulate PKCε. TBK1 was originally identified in a 
yeast two-hybrid screen using TANK as a bait 
(Pomerantz and Baltimore, 1999).  
T2K was cloned as part of a TRAF2-binding  
 
 
Figure 1: Schematic representation of the kinase subunit of the IKK complex (IKKα and IKKβ) and the IKK-related kinases (IKKi and 
TBK1). 
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complex that exhibits kinase activity towards IκBα in 
vitro (Bonnard et al., 2000). At almost exactly thesame 
time, another IKK-related kinase was also 
characterized and named IKKε/IKKi.  
Peters and colleagues found IKKε in a database search 
for proteins similar to IKKα and IKKβ, whereas Akira's 
group isolated IKKi (the "i" standing for inducible 
IKK, see below) in a subtractive hybridization screen 
of a cDNA library from LPS-stimulated mouse macro-
phages (Peters et al., 2000; Shimada et al., 1999). 
TBK1 and IKKi display 64% overall sequence identity 
(Fig. 1). In contrast to the kinase subunits of the 
canonical IKK complex (IKKα and IKKβ) and TBK1, 
which are constitutively expressed in virtually allcell 
types, IKKi is predominantly expressed in specific 
tissues such as the pancreas, thymus, spleen, and 
peripheral blood leukocytes (Shimada et al., 1999). It is 
also expressed at very low levels in specific cell lines 
(Bibeau-Poirier et al., 2006; Gravel and Servant, 2005; 
Honda et al., 2005). Importantly, IKKi mRNA can be 
induced in response to exposure to LPS, viral infection, 
or a number of NF-κB-inducing cytokines (Bibeau-
Poirier et al., 2006; Kravchenko et al., 2003; Shimada 
et al., 1999; Wang et al., 2005). 
Like IKKα and IKKβ, the IKK-related kinases contain 
an N-terminal kinase domain and a C-terminal Leucine 
Zipper (LZ) thought to be involved in homo and 
heterodimerization of the protein kinases (Fig. 1). A 
potential Helix-Loop-Helix (HLH) motif is also presnt 
and, as demonstrated for IKKβ (Delhase et al., 1999), 
may be involved in the regulation of 
phosphotransferase activity. The kinase domain of 
IKKi shares 33% and 31% sequence identity with 
IKK α and IKKβ respectively. As such, overexpression 
of both kinases induces NF-κB activation (Peters et al., 
2000; Pomerantz and Baltimore, 1999; Shimada et al., 
1999). However, the IKK-related kinases are not parof 
the classical IKKγ-containing IKK complex (Fujita et 
al., 2003; Peters et al., 2000; Shimada et al., 1999) and 
their role in controling the NF-κB pathway in response 
to proinflammatory stimuli or PRR engagement 
remains uncertain. The only evidence in favor of a role
of TBK1 in regulating NF-κB activation are indirect 
and come from mouse models that revealed functional 
similarities between IKKβ and the IKK-related kinases. 
Notably, TBK1-deficient mice are phenol-typically 
similar to IKKγ, IKKβ- and p65-deficient mice, which 
die at E14.5 due to liver degeneration and apoptosis 
(Bonnard et al., 2000). However, mouse embryonic 
fibroblasts (MEFs) deficient for IKKi or TBK1 show 
normal IκBα degradation and NF-κB DNA-binding 
activity in response to classical NF-κB inducers 
including TNFα, IL-1β and LPS (Bonnard et al., 2000; 
Hemmi et al., 2004; Kravchenko et al., 2003). 
Intriguingly, the induction of well-characterized NF-κB 
target genes such as IL6, MCP1, COX2 and ICAM1 
was abrogated in MEFs lacking either IKKi or TBK1. 
Therefore, phosphorylation of NF-κB subunits by 
TBK1 was proposed to explain the observed defects in 
the transactivation of specific NF-κB target genes 
(Bonnard et al., 2000). It is worth mentioning that 
phosphorylation of p65/RelA at serine 536 by IKKβ 
and IKKα was shown to be an essential modification 
required in the second phase of NF-κB activation. This 
event plays a key role in determining both the strength 
and duration of the NF-κB-mediated transcriptional 
response (Chen et al., 2005; Lawrence et al., 2005). 
Interestingly, both IKKi and TBK1 also target 
p65/RelA at serine 536 (see Table I), a process clearly 
involved in the induction of NF-κB-regulated genes 
(Buss et al., 2004; Fujita et al., 2003). However, n ither 
a defect in p65 phosphorylation or in NF-κB dependent 
gene transcription was confirmed in more recent 
studies using MEFs isolated from TBK1-IKKi double 
knockout mice (Adli and Baldwin, 2006; Hemmi et al., 
2004). Thus, the physiological role of the IKK-relat d 
kinases in NF-κB activation in response to 
proinflammatory cytokines or PRR engagement is still 
not fully understood. 
It is possible that under conditions of overexpres-sion 
(as observed in certain cancers (see below)) and/or 
hyperactivation, the NF-κB pathway could become a 
significant target of IKK-related kinases. Indeed, when 
overexpressed, TBK1 and IKKi activate the NF-κB 
pathway and are able to induce the phosphorylation of 
IκBα (Peters et al., 2000; Pomerantz and Baltimore, 
1999; Shimada et al., 1999). Interestingly, in contrast to 
IKK β, the enzymes TBK1 and IKKi phosphorylate 
only one (serine 36) of the two phosphoacceptor sites 
present in IκBα (Peters et al., 2000; Shimada et al., 
1999; Tojima et al., 2000). Why only one 
phosphorylation event occurs in the IκBα 
phosphodegron motif –DSGXXS- is unclear. 
Overexpression of IKKi is known to effectively drive 
IκBα degradation (Boehm et al., 2007; Eddy et al., 
2005), indicating that phosphorylation of serine 36 may 
facilitate the phosphorylation of the protein on serin  
32 by another kinase, leading to its degradation. 
Phosphorylation of the adaptor protein TANK by IKKi 
could also induce the release of TRAF2 followed by 
the subsequent activation of the IKK complex (Nomura 
et al., 2000) (see Table I). Furthermore, overexpression 
of these kinases was shown to phosphorylate NF-κB 
members such as p65 and c-Rel (Adli and Baldwin, 
2006; Harris et al., 2006). 
The IKK-related kinases, key players in 
the induction of type I interferon 
Whereas the role of the IKK-related kinases in 
regulating the canonical NF-κB pathway is still 
uncertain, their roles in type I IFN production through 
the phosphorylation and activation of IRF-3 and IRF-7 
transcription factors is well established (Fitzgerald et 
al., 2003; Sharma et al., 2003). In most cells, including 
fibroblasts, macrophages and conventional dendritic 
cells, IRF-3 and IRF-7 are important players in the
induction of type I IFN following RLRs and TLR3/4 
engagement (Honda et al., 2005; Sato et al., 2000; 
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Tamura et al., 2008) and both kinases phosphorylate 
IRF-3 and IRF-7 at key C-terminal residues (Caillaud 
et al., 2005; Clement et al., 2008a; Mori et al., 2004; 
Panne et al., 2007; tenOever et al., 2004). Whereas 
IRF-7 can be induced at the transcriptional level, IRF-3 
is found latent in the cytoplasm. Upon phosphorylation 
of the C-terminal region by TBK1 or IKKi, IRF-3 
homodimerizes or heterodimerizes with IRF-7 followed 
by its nuclear accumulation and binding to ISRE found 
in numerous genes such as type I IFN (see (Tamura et 
al., 2008) for a recent review). Another IRF family 
member, IRF-5, is also involved in IFN type I 
induction (Yanai et al., 2007) and can also be 
phosphorylated by TBK1 or IKKi (Cheng et al., 2006; 
Lin et al., 2005; Schoenemeyer et al., 2005). However, 
how IRF-5 participates in the transcriptional regulation 
of type I IFNs genes is not completely understood. 
Since the discovery of TBK1 and IKKi, extensive 
characterization of the signaling pathways leading to 
the activation of IRF-3 and IRF-7 in response to 
pathogen infection has led to the identification of 
several positive scaffolding proteins regulating the 
phosphotransferase activities of the two kinases. These 
regulators include NEMO/IKKγ (Zhao et al., 2007), 
FADD (Balachandran et al., 2004), TRADD (Michallet 
et al., 2008), TRAF3 (Hacker et al., 2006; Oganesyan 
et al., 2006), TANK (Gatot et al., 2007; Guo and 
Cheng, 2007; Nomura et al., 2000; Rothe et al., 1996), 
NAP1 (Fujita et al., 2003; Sasai et al., 2005), HSP90 
(Yang et al., 2006), SINTBAD (Ryzhakov and 
Randow, 2007), DDX3 (Schroder et al., 2008; Soulat et 
al., 2008) and STING/MITA (Ishikawa and Barber, 
2008; Zhong et al., 2008). In addition, intracellular 
RNA sensors such as RIG-1 (Yoneyama et al., 2004) 
and MDA-5 (Andrejeva et al., 2004), which signal 
through the mitochondrial antiviral signaling adaptor 
MAVS (also known as Cardif, VISA, and IPS-1) 
(Kawai et al., 2005; Meylan et al., 2005; Seth et al., 
2005; Xu et al., 2005), have been found to activate the 
IKK-related kinases in response to infection by RNA 
viruses. The detection of intracellular DNA (particulary 
B-DNA) by DNA sensors, which rely on IRF-3 for type 
I IFN production, was also recently proposed to impact 
on the activity of IKK-related kinases. DAI (also know 
as DLM-1/ZBP1) is a DNA sensor that assembles with 
TBK1 and IRF-3 upon dsDNA treatment and was 
suggested to be involved in type I IFN response 
(Takaoka et al., 2007). However, recent studies in DAI-
deficient cells failed to identify a phenotype suggesting 
the implication of other DNA sensors (Charrel-Dennis 
et al., 2008; Wang et al., 2008). Importantly, whereas 
TBK1 and IKKi play redundant roles in macrophages 
following RIG-I engagement (Perry et al., 2004), a 
TBK1-dependent pathway is dominant for type I IFN 
response upon intracellular DNA recognition (Charrel-
Dennis et al., 2008; Miyahira et al., 2009; Nociari et al., 
2009). This possibly suggests an important role of the 
scaffolding regulators described above in ordering the 
formation and/or recruitment of specific oligomeric 
complexes upon exposition to different stimuli. At the 
level of transcriptional regulation, GRIP1 was recently 
identified as a new cofactor of IRF-3 dimers (Reily et 
al., 2006). Negative regulators including the SHP-2 
phosphatase (An et al., 2006), SIKE (Huang et al., 
2005), A20 (Lin et al., 2006), LGP-2 (Rothenfusser et 
al., 2005), NLXR1 (Moore et al., 2008) and CYLD 
(Zhang et al., 2008) add to the complex puzzle. Some 
of these important findings have been extensively 
reviewed elsewhere (Bowie and Unterholzner, 2008; 
Hacker and Karin, 2006; Honda and Taniguchi, 2006; 
Kassel and Herrlich, 2007; Seth et al., 2006; Tamur et 
al., 2008) and will not be discussed further here. More 
recently, the IKK-related kinases have been implicated 
in oncogenesis (Boehm et al., 2007; Chien et al., 2006; 
Clement et al., 2008b; Eddy et al., 2005; Korherr et al., 
2006; Lee and Hung, 2008). The following discussion 
will focus on the potential oncogenic roles of the IKK-
related kinases and their different substrates (Table 1). 
The IKK-related kinases in oncogenesis 
The role of the NF-κB pathway in the molecular 
etiology of cancer has been well established using 
mouse models with tissue-specific ablation of the IKKβ 
gene in epithelial cells, bone-marrow-derived 
macrophages and hepatocytes (Greten et al., 2004; 
Maeda et al., 2005) and see (Coussens and Werb, 2002;
Karin, 2008; Karin and Greten, 2005; Karin et al., 
2006) for reviews. Moreover, study of IKKαAA knock-
in mice, which express a catalytically inactive kinase 
mutant, revealed an important role for IKKα in 
metastatogenesis (Luo et al., 2007). The fact that 
ectopic expression of the IKK-related kinases leads to 
activation of the NF-κB pathway (see above) might 
suggest that these kinases could also be involved in 
cancer develop-ment. Notably, recent findings point 
towards a role for TBK1 and IKKi in Ras-induced 
oncogenic transformation (Fig. 2). TBK1 was identified 
as a RalB effector in the Ral-guanine nucleotide 
exchange factor (GEF) pathway that is required for 
Ras-induced transformation of certain cell types. On 
the other hand, a functional screen identified IKKi as a 
kinase that acts downstream of the phosphatidylinositol 
3-kinase (PI3K)-Akt pathway and cooperate with 
activated MEK1/2 to promote cellular transformation. 
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Figure 2: Pivotal contribution of the IKK-related kinases to oncogenic Ras-induced tumorigenesis. Recent findings highlight a role 
of TBK1 and IKKi in Ras-induced oncogenic transformation. In the uncontrolled proliferation of transformed cells, IKKi plays a role 
downstream of the PI3KAkt pathway, whereas TBK1 most likely acts as a RalB effector in the RalGEF pathway. 
 
TBK1 and RalB signaling 
The Ras-like (Ral) GTPases RalA and RalB are two 
close relatives of the founding member of the Ras 
GTPase superfamily. The Ral proteins are involved in a
variety of regulatory systems known to participate in 
oncogenic signaling cascades. Indeed, modulation of 
Ral GTPase activity was shown to influence the state of 
activation of Src, Jnk, and p38 kinases, phospholipase 
D, and NF-κB, Stat3 and transcription factors of the 
Forkhead family (Camonis and White, 2005). 
Importantly, RalGEF-induced Ral activation was found 
to be necessary and sufficient for Ras-dependent 
transformation of a variety of human cell types (Hamad 
et al., 2002; Lim et al., 2006; Rangarajan et al., 2004). 
Ral GTPases also control secretory events through the 
exocyst. The exocyst is a multisubunit complex whose 
core elements include Sec3, Sec5, Sec6, Sec8, Sec10, 
Sec15, Exo70 and Exo84. It is involved in the intricate 
secretory vesicle sorting and delivery events requir d 
establishing function-ally and architecturally discrete 
plasma membrane domains (Camonis and White, 
2005). Sec5 and Exo84 are both direct effectors of Ral. 
While studying the contribution of Ral GTPase effector 
proteins to Ral function in normal and tumorigenic  
epithelial cells, Chien and colleagues observed that
RNAi-mediated depletion of Sec5 induces apoptosis of 
a variety of tumor cell lines (Chien et al., 2006). To 
understand the molecular basis of this effect, they 
immunoisolated the exocyst complex from epithelial 
cells and identified TBK1 as a co-precipitating protein. 
They further showed that RalB activation promotes 
TBK1/Sec5 assembly and that TBK1 can 
phosphorylate Sec5 in vitro (see Fig. 3A and Table I). 
Silencing of TBK1 expression by RNAi was found to 
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mimic depletion of RalB or Sec5 and induce tumor cell 
apoptosis. Interestingly, non-tumorigenic epithelial 
cells do not depend on TBK1 for survival (Chien et al.,
2006). The selective dependence of transformed cells 
on TBK1 was also reflected in the enzyme's 
phosphotransferase activity, which was higher in 
transformed cells than in non-tumorigenic epithelial 
cells. Furthermore, studies using TBK1-/- fibroblasts 
revealed that TBK1 expression was required for cells to 
tolerate transforming levels of oncogenic K-RasG12V. 
This study also established that RalB and Sec5 were 
required for activation of the host defense pathway. 
Whereas Ras activity was suppressed in non-
transformed epithelial cells in response to TLR3  
signaling stimulated by poly(I:C) treatment, Ral 
GTPases were activated and this activation correlated 
with the phosphorylation of IRF-3. Moreover, siRNA-
mediated depletion of Sec5 severely impaired not only
the nuclear accumulation of IRF-3, but also the 
induction of ISG56 and IFNβ following Sendai virus 
(SeV) infection or poly(I:C) treatment. In summary, the 
RalB/TBK1 pathway is required for the survival of 
Ras-transformed cells and to activate the innate 
immune response in non-tumorigenic cells (Fig. 4). 
Another recent study provides evidence for a role of 
TBK1 in the tumorigenesis process. Using a genome-
wide phenotypic screen based on the overexpression of 
250,000 cDNAs in HEK 293 cells combined with the 
transfer of culture supernatants onto HUVEC cells, 
Korrher and colleagues identified TBK1 and TRIF as 
new effectors of vascularization (Korherr et al., 2006). 
Overexpression of TRIF and TBK1 in HEK 293 cells 
resulted in the secretion of a complex mixture 
containing endothelial growth factors such as IL-8 and 
RANTES, as well as the anti-proliferative cytokine 
IFNβ. The secreted mixture displayed significant 
proangiogenic properties on endothelial cells. In 
addition to HEK 293 cells, the authors analyzed the 
proliferative response of endothelial cells to 
supernatants isolated from MCF-7, PC-3, and KB-3-1 
cancer cells transiently transfected with the gene 
encoding TBK1. They confirmed that the autocrine 
effect of TBK1 is observed in various cancer cell lines. 
Interestingly, these cancer cell lines already show 
increased activity of TBK1 (see above). Their study 
also showed some unexpected findings: TBK1 was up-
regulated under hypoxic conditions, as well as in solid 
breast and colon tumors. This is the first report 
demonstrating modulation of TBK1 at the protein level. 
Overall, these two studies propose a role of TBK1 in 
tumor cell survival and angiogenesis. However, the 
molecular mechanisms explaining the possible effects 
of TBK1 in oncogenesis remain to be characterized. 
Breast cancer and the NF-κB pathway. 
Is IKKi the missing link?  
Inflammatory breast cancer is the most aggressive form
of locally advanced breast cancer with a high metasta ic 
potential. At the molecular level, microarray and qPCR 
analyses have revealed an 'NF-κB signature' in this 
form of breast cancer (Lerebours et al., 2008; Van 
Laere et al., 2006). Interestingly, the first evidenc  
implicating IKKi in tumor development was in breast 
cancer. IKKi was found to be constitutively expressed 
in two-thirds of the human breast cancer samples 
analyzed, as well as in several human breast cancer cell 
lines (Eddy et al., 2005). Casein kinase 2 (CK2) was 
proposed to be involved in the increased expression 
level of IKKi. Most importantly, the NF-κB pathway is 
thought to contribute to the uncontrolled  
cellular proliferation of IKKi-expressing cells, since 
overexpression of an inactive mutant of IKKi reduces 
the expression of the cyclin D1 gene targeted by NF-κB 
(Fig. 3B). It also reduces the ability of breast cancer 
cells to grow in soft agar and to form invasive colonies 
in Matrigel. 
Mutation of Ras proteins or hyperactivation of 
downstream effector pathways, principally the 
mitogen-activated protein kinase (MAPK) and PI3K 
pathways, occurs in several epithelial cancers including 
breast cancers ((Downward, 2003) and Fig. 2). An 
elegant functional genomic approach was used to 
identify protein kinases that have the potential to 
replace activated Akt and cooperate with a 
constitutively active MAPK pathway to drive 
tumorigenesis of immortalized human embryonic 
kidney epithelial cells (Boehm et al., 2007). In this 
study, IKKi was identified among four kinases with 
transforming potential (Fig. 3B). Interestingly, the 
authors found copy-number amplification of the 1q32 
region, which includes the IKBKE locus, in 16.3% of 
breast cancer cell lines and in several primary human 
breast cancer specimens. No somatic mutation was 
found in the IKBKE gene, and no association was 
observed between the IKBKE copy-number gain and 
the estrogen receptor or HER2/neu status. IKBKE 
amplification correlated with overexpression of IKKi in 
several breast cancer cell lines such as MCF-7 and ZR-
75-1. Silencing experiments with shRNAs confirmed 
that IKKi is required for the proliferation and survival 
of ZR-75-1 cells. Interestingly, knocking down the 
expression levels of both IKKi and TBK1 was required 
to diminish the viability of MCF-7 cells. This 
observation also supports a role for TBK1 in 
oncogenesis as discussed above. Amplification of 
chromosome 1q is also observed in other cancers such 
as multiple myeloma (Kuehl and Bergsagel, 2002) and 
head and neck cancer (Bauer et al., 2008). Thus, it 
would be interesting to verify whether IKKi is also up-
regulated in these cancers. 
At the molecular level, the overexpression of IKKi 
observed in breast cancer cell lines resulted in 
increased expression of two NF-κB-regulated genes, 
MMP9 and BCL2, both of which were down-regulated 
when IKBKE expression was suppressed. Moreover, 
immunohistochemical studies in patient-derived breast 
cancer tissue samples revealed nuclear staining for c-
Rel, a recently described substrate of IKKi (Table I).  
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Figure 3: (A) TBK1 interacts with Sec5 in the exocyst complex. The contribution of Sec5 to TBK1 activation occurs independently of 
exocyst integrity. Rather, the proposed model suggests that RalB-Sec5 complex formation exposes a cryptic TBK1 interaction domain 
that recruits TBK1 into a kinase activation complex. The molecular mecha-nism responsible for TBK1-dependent tumor cell survival 
remains to be characterized but could involve the NF-κB pathway. (B) IKKi is an essential effector of Akt cellular transformation. The 
NF-κB pathway contributes to the oncogenic potential of IKKi. How the PI3-kinase pathway activates IKKi is presently unknown. 
 
This protein had previously been reported to 
accumulate in the nuclei of breast cancer cells (Sovak 
et al., 1997) and to contribute to tumorigenesis of the 
mammary gland in an MMTV-LTR-c-Rel transgenic 
mouse model (Romieu-Mourez et al., 2003). IKKi 
modulates c-Rel activity through direct 
phosphorylation of the transactivation domain (Harris 
et al., 2006).  
However, even though nuclear accumulation of c-Rel 
was observed in HEK 293T cells, IKKi-induced 
phosphorylation was insuffi-cient to significantly 
induce its transactivation potential. Thus, additional 
signaling cascades are likely to be required for full 
activation of c-Rel. 
In addition to c-Rel and RelB (Eddy et al., 2005),  
RelA/p65 was observed to accumulate in the nuclei of  
 
primary human breast tumor specimens (Sovak et al., 
1997). Furthermore, in many cancer cell lines, 
expression levels of IKKi correlate with p65 
phosphorylation at serine 536 (Adli and Baldwin, 
2006). It is worth mentioning that IKKi was also shown 
to enhance the activity of p65 following its 
phosphorylation at serine 468 (Mattioli et al., 2006). 
Finally, IKKi also interacts with NF-κB2/p100 and p52 
following TNFα stimulation (Wietek et al., 2006). Gel 
filtration experiments suggest that IKKi and p52 are 
components of a 600-kDa complex. This interaction 
promotes transcription of p52-dependent genes in a 
ternary complex with p65/RelA. Although the kinase 
activity of IKKi is essential for this process, p52 does 
not seem to be a direct target, again suggesting that 
p65/RelA may be the preferred substrate of the kinase. 
Are other substrates of IKK-related 
kinases involved in tumorigenesis? 
It is intriguing that while the activity of IKK-related 
kinases is linked to cancer cell survival (see above),  
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Table I. Substrates of the IKK-related kinases. 
 
these kinases act on transcription factors with tumor 
suppressor properties, namely IRF-3, -5, and -7 (Table 
I and Fig. 4). Upon activation by TBK1 or IKKi 
following viral or bacterial infections, these 
transcription factors ultimately lead to pathogen 
clearance. This occurs through the induction of type I 
IFN and of several IFN-stimulated genes (ISGs) 
involved in host defense cellular processes.  
These processes include protein translation shutdown, 
cell cycle withdrawal, apoptosis, and hematopoietic cell 
regulation such as dendritic cell activation. Notably, 
type I IFN signaling induces p53 accumulation 
(Takaoka et al., 2003). Thus, at first glance, one can
argue that the IKK-related kinases may also counterac  
tumor development through their effect on type I IFN 
synthesis. However, several cancers exhibit specific 
mutations in components of the IFN signaling pathway 
(Stojdl et al., 2000) and are therefore resistant to he 
growth-inhibitory effects of type I IFN. Since these 
cytokines are known to act by paracrine and autocrine 
mechanisms, transformed cells that rely on IKK-related 
kinases for survival and proliferation are likely to be 
unresponsive to type I IFN, thus shifting the 
equilibrium toward tumor progression (Fig. 4). On the 
other hand, IRF-3 is known to possess tumor 
suppressor activities that are unrelated to the protein's 
effect on type I IFN synthesis, but are directly linked to 
its effect on apoptosis. Studies have revealed that IRF-3 
can transactivate a large number of genes, including 
ISG56, TRAIL, and NOXA, which can abrogate 
protein synthesis or induce apoptosis in a p53-
independent manner (Grandvaux et al., 2002a; Guo et 
al., 2000; Kirshner et al., 2005; Lallemand et al., 2007; 
Weaver et al., 2001). IRF-3 also activates transcription 
of the gene encoding promyelocytic leukemia protein 
(PML), leading to p53-dependent growth inhibition of 
cancer cell lines (Kim et al., 2006; Kim et al., 2007). 
The role of IRF-7 in oncogenesis is unclear. According 
to Zhang and colleagues, IRF-7 itself has oncogenic 
potential, as evidenced by its ability to induce tumor  
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Figure 4: Transformed cells rely on the IKK-related kinases for cell proliferation and viability. Both the expression and the activity 
of IKKi and TBK1 can be increased in transformed tissues or cancer-derived cell lines. The IKK-related kinases depend on effectors of 
the NF-κB pathway, such as c-Rel and p65/RelA in order to antagonize apoptotic signals that are normally activated when cells loose 
contact with the extracellular matrix or following genotoxic insults. Cyclin D1 induction reduces the dependency of growth signals and 
promotes G1-S transition. The role of phosphoryla-ted Sec5 in TBK1-induced cancer cell survival remains to be elucidated. On the other 
hand, following exposition to PAMPs, targeted cells use IKK-related kinases to induce a set of anti-viral genes like type I IFN. IFNs are 
strong inducers of cell cycle arrest. However, several cancers exhibit specific mutations of gene products in the IFN pathway and are 
therefore resistant to the growth inhibitory effect of type I IFN. 
 
formation in nude mice and to cause anchorage-
independent growth in NIH 3T3 cells (Zhang et al., 
2004). These authors suggested that IRF-7 might 
cooperate with the viral onco-protein LMP-1 in EBV-
immortalized B cells or CNS lymphoma cells in order  
to achieve cellular transformation. Conversely, a recent 
study pointed to the antitumor effector functions of 
IRF-7. Adenoviral transduction of an active form of 
IRF-7 into macrophages was found to up-regulate 
genes such as TRAIL, IL15, IL12p35, ISG56, and 
CD80 and also down-regulate transcription of  
proangio-genic/metastatic genes such as VEGF and 
MMP2. Thus, IRF-7 increased the antitumor properties 
of primary macrophages while reducing their pro-
tumorigenic effects (Romieu-Mourez et al., 2006). 
IRF-5 is also a candidate tumor suppressor gene that 
mediates cell cycle arrest and apoptosis (reviewed in 
(Tamura et al., 2008)).  
In primary hematological malignancies such as acute 
lympho-blastic leukemia, chronic lymphocytic 
leukemia and acute myeloid leukemia, IRF-5 
expression is frequently down-regulated or absent 
(Barnes et al., 2003).  
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Overexpression of IRF-5 reduces colony formation of 
A549 lung cancer cells and HCT116 colorectal cancer 
cells (Mori et al., 2002), and it inhibits growth of BJAB 
tumor cells in vivo (Barnes et al., 2003). 
STAT1 and c-Jun, novel substrates of 
IKKi 
As key players in the interferon pathway, proteins 
known as signal transducers and activators of 
transcription (STAT) proteins contribute to the 
induction of numerous genes known to establish a 
formidable barrier against viral infection. Recently, 
Tenoever and colleagues established a molecular link 
between IKKi and the formation of ISGF3, composed 
of the STAT1-STAT2 heterodimer and IRF-9 
(Tenoever et al., 2007). They showed that IKKi 
phosphorylates STAT1 following treatment with IFNβ. 
In vitro kinase assays combined with mass 
spectrometry identified serine 708 as the 
phosphorylated residue. This post-translational 
modifycation allows formation of a more stable 
STAT1-STAT2 heterodimer, which is likely to be 
essential for binding to the ISRE sequence located  
in a subset of genes involved in antiviral immunity. 
Thus, IKKi may be involved in defining ISGF3 binding 
specificity. 
The STAT proteins have also been extensively studied 
for their role in oncogenesis. For instance, constitutive 
activation of STAT1, STAT3, and STAT5 has been 
observed in different human primary tumors and cell
lines derived from breast cancer, multiple myeloma, 
head and neck cancer, leukemia, lymphoma, and lung 
cancer (Bowman et al., 2000; Watson, 2001). However, 
unlike the clear involvement of STAT3 and STAT5 in 
oncogenesis, the role of STAT1 remains obscure and 
contro-versial. While STAT3 and STAT5 are clearly 
recognized as oncogenic transcription factors, the 
STAT1 pathway has been predominantly associated 
with the inhibition of cell proliferation and tumor 
suppression (Desrivieres et al., 2006; Watson, 2001). 
On one hand, STAT1 can promote tumor cell death 
through transcriptional regulation of genes encoding 
proteins such as death receptors and ligands, caspases, 
iNOS, Bcl-xL, and p21Cip1 (for reviews see (Bowman et 
al., 2000; Bromberg and Darnell, 2000; Kim and Lee, 
2007)). On the other hand, according to the recent 
findings of Yarilina and colleagues, STAT1 in myeloid 
cells could enhance tumor progression by accelerating 
inflame-mation during the early stages of 
inflammation-associated tumorigenesis (Yarilina et al., 
2008). Indeed, TNFα, a well-known protumorigenic 
cyto-kine (Lin and Karin, 2007), can stimulate 
macrophages to produce low levels of IFNβ, which can 
in turn activate Jak-STAT signaling. Once activated, 
the Jak-STAT pathway act in synergy with other TNF-
induced signals to maintain the expression of 
inflammatory cytokines. It also leads to increased 
expression of IKKi, IRF-7, and STAT1. Thus, STAT1 
activation could play opposing roles in cancer 
development (Fig. 4). As mentioned above, IKKi 
expression is also increased in breast tumors and it may 
therefore play a role in the constitutive activation f 
STAT1 seen in breast tumor-derived cell lines 
(Bowman et al., 2000; Watson, 2001). 
The transcriptional activator c-Jun (cellular Jun) has 
inherent oncogenic potential (Vogt and Bader, 2005). It 
has been suggested that IKKi is involved in TNFα and 
LPS-induced MMP-3 and MMP-13 gene expressions 
via phosphorylation and activa-tion of c-Jun (Sweeney 
et al., 2005). The phospho-acceptor site(s) on c-Jun was 
however not identified and more work is necessary to 
ascertain whether c-Jun transcriptional activity is 
regulated by IKKi. 
Conclusion 
There is now compelling evidence that the transcription 
factor NF-κB plays a key role in cancer development 
and progression. Thus, the recent suggestion that the 
IKK-related kinases TBK1 and IKKi also regulate the 
proliferation and survival of cancer cells was not totally 
unexpected. These new findings should increase our 
under-standing of the complex relationship between 
innate immune effectors and the signaling events that 
drive tumor formation. Some of the future questions 
that should be high on the priority list of investigators 
analyzing the role of these kinases in tumor 
development are the following. How the kinase activity 
of TBK1 is increased in cancer-derived cell lines in the 
absence of any apparent increased in expression level? 
Is this related to distinct scaffold proteins that facilitate 
assembly of TBK1 and IKKi subcomplexes (Chau et 
al., 2008) or is it related to the a decrease in the 
expression of the tumor supressor CYLD (Zhang et al., 
2008)? Is the effect of TBK1 on tumor cell survival and 
angiogenesis dependent on the NF-κB pathway? What 
is the molecular basis of IKKi overexpression in breast 
tumors in the absence of amplification of the IKBKE 
locus, and is this related to increase NF-κB signaling? 
Are IRF-3 and IRF-7 activated in transformed cells that 
rely on TBK1 or IKKi for their proliferation and 
survival? If yes, then what is the role of the 
proapoptotic functions of these transcription factors 
that are unrelated to their effect on type I IFN 
synthesis? Are there other substrates for these kinases 
that could explain their effect on tumor cell 
proliferation and survival? TBK1 and IKKi are new 
effectors implicated in tumor progression and might 
therefore represent new opportunities for drug 
development. Notably, the availability of compounds 
like SU6668, which targets TBK1 and other kinases, 
may help dissect out the role of IKK-related kinases in 
cancer (Godl et al., 2005). 
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